

TDMS No. 88133 - 08

**P05: INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS
ABRIDGED) (a)**

Date Report Requested: 05/17/2010

Test Type: CHRONIC

Trimethylolpropane triacrylate

Time Report Requested: 09:26:54

Route: SKIN APPLICATION

CAS Number: 15625-89-5

First Dose M/F: 12/13/04 / 12/13/04

Species/Strain: MICE/B6C3F1

Lab: SRI

F1_M3

C Number: C88133C
Lock Date: 10/30/2007
Cage Range: ALL
Date Range: ALL
Reasons For Removal: 25022 ACCK
25019 MSAC
Removal Date Range: ALL
Treatment Groups: Include ALL
Study Gender: Both
TDMSE Version: 2.2.0

25021 TSAC

25020 NATD

Test Type: CHRONIC

Trimethylolpropane triacrylate

Time Report Requested: 09:26:54

Route: SKIN APPLICATION

CAS Number: 15625-89-5

First Dose M/F: 12/13/04 / 12/13/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
------------------	---------	-----------	-----------	-----------

Disposition Summary

Animals Initially In Study	65	65	65	65
Early Deaths				
Moribund Sacrifice	8	7	10	4
Natural Death	12	8	11	8
Survivors				
Terminal Sacrifice	30	35	29	38
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(49)
Gallbladder	(38)	(41)	(37)	(43)
Carcinoma, Metastatic, Pancreas	1 (3%)			
Intestine Large, Cecum	(42)	(43)	(40)	(44)
Adenoma	1 (2%)	1 (2%)		
Carcinoma			1 (3%)	
Intestine Large, Colon	(44)	(44)	(41)	(46)
Intestine Large, Rectum	(45)	(44)	(41)	(47)
Intestine Small, Duodenum	(40)	(43)	(40)	(46)
Adenoma		1 (2%)		
Intestine Small, Ileum	(42)	(43)	(40)	(45)
Intestine Small, Jejunum	(40)	(42)	(40)	(44)
Carcinoma	2 (5%)		4 (10%)	1 (2%)
Hepatocolangiocarcinoma, Metastatic, Liver			1 (3%)	
Liver	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (2%)			
Carcinoma, Metastatic, Pancreas	1 (2%)			
Hemangioma			1 (2%)	
Hemangiosarcoma	2 (4%)	1 (2%)	4 (8%)	5 (10%)
Hepatoblastoma	4 (8%)	4 (8%)	3 (6%)	5 (10%)
Hepatoblastoma, Multiple	1 (2%)	1 (2%)	1 (2%)	
Hepatocellular Adenoma	12 (24%)	14 (28%)	14 (28%)	15 (30%)
Hepatocellular Adenoma, Multiple	22 (44%)	21 (42%)	18 (36%)	19 (38%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Trimethylolpropane triacrylate

Time Report Requested: 09:26:54

Route: SKIN APPLICATION

CAS Number: 15625-89-5

First Dose M/F: 12/13/04 / 12/13/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Hepatocellular Carcinoma	13 (26%)	13 (26%)	15 (30%)	14 (28%)
Hepatocellular Carcinoma, Multiple	9 (18%)	1 (2%)	4 (8%)	11 (22%)
Hepatocholangiocarcinoma	2 (4%)		3 (6%)	
Mesentery	(9)	(8)	(11)	(6)
Carcinoma, Metastatic, Pancreas	1 (11%)			
Hemangiosarcoma			1 (9%)	
Hepatoblastoma, Metastatic, Liver			1 (9%)	
Hepatocellular Carcinoma, Metastatic, Liver			1 (9%)	
Hepatocholangiocarcinoma, Metastatic, Liver			1 (9%)	
Oral Mucosa	(0)	(1)	(0)	(0)
Pancreas	(50)	(49)	(45)	(50)
Carcinoma	1 (2%)			
Hepatoblastoma, Metastatic, Liver			1 (2%)	
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)		1 (2%)	
Salivary Glands	(50)	(50)	(50)	(50)
Stomach, Forestomach	(50)	(49)	(48)	(50)
Carcinoma, Metastatic, Pancreas	1 (2%)			
Squamous Cell Papilloma	3 (6%)	1 (2%)		
Stomach, Glandular	(48)	(49)	(44)	(49)

CARDIOVASCULAR SYSTEM

Blood Vessel	(1)	(0)	(0)	(1)
Heart	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (2%)			
Hemangiosarcoma	1 (2%)			1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver		1 (2%)		
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)			

ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(49)	(47)	(50)
Carcinoma, Metastatic, Liver	1 (2%)			
Subcapsular, Adenoma	6 (12%)	10 (20%)	4 (9%)	4 (8%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Trimethylolpropane triacrylate

Time Report Requested: 09:26:54

Route: SKIN APPLICATION

CAS Number: 15625-89-5

First Dose M/F: 12/13/04 / 12/13/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Adrenal Medulla	(49)	(49)	(46)	(50)
Pheochromocytoma Benign				1 (2%)
Islets, Pancreatic	(50)	(49)	(44)	(50)
Adenoma		5 (10%)	1 (2%)	
Parathyroid Gland	(48)	(48)	(48)	(50)
Pituitary Gland	(50)	(48)	(49)	(50)
Pars Intermedia, Adenoma			1 (2%)	
Thyroid Gland	(50)	(47)	(46)	(48)
Hepatocolangiocarcinoma, Metastatic, Liver	1 (2%)			
Follicular Cell, Adenoma		1 (2%)	1 (2%)	1 (2%)
GENERAL BODY SYSTEM				
Tissue NOS	(2)	(1)	(1)	(0)
Carcinoma, Metastatic, Pancreas	1 (50%)			
Hepatoblastoma, Metastatic, Liver			1 (100%)	
GENITAL SYSTEM				
Coagulating Gland	(0)	(0)	(1)	(0)
Epididymis	(49)	(50)	(50)	(50)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (2%)			
Carcinoma, Metastatic, Pancreas	1 (2%)			
Preputial Gland	(50)	(50)	(50)	(50)
Prostate	(50)	(49)	(49)	(50)
Seminal Vesicle	(50)	(50)	(49)	(50)
Carcinoma, Metastatic, Pancreas	1 (2%)			
Testes	(50)	(50)	(50)	(50)
Interstitial Cell, Adenoma	1 (2%)	2 (4%)	1 (2%)	
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(49)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Trimethylolpropane triacrylate

Time Report Requested: 09:26:54

Route: SKIN APPLICATION

CAS Number: 15625-89-5

First Dose M/F: 12/13/04 / 12/13/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Hemangiosarcoma	1 (2%)	1 (2%)	1 (2%)	
Lymph Node	(5)	(6)	(2)	(1)
Mediastinal, Carcinoma, Metastatic, Harderian Gland				1 (100%)
Mediastinal, Carcinoma, Metastatic, Pancreas	1 (20%)			
Lymph Node, Mandibular	(48)	(48)	(46)	(46)
Carcinoma, Metastatic, Harderian Gland				2 (4%)
Lymph Node, Mesenteric	(48)	(47)	(45)	(50)
Hemangiosarcoma	1 (2%)			
Spleen	(49)	(48)	(45)	(49)
Hemangiosarcoma	4 (8%)	1 (2%)	1 (2%)	1 (2%)
Thymus	(48)	(48)	(44)	(47)
Hemangiosarcoma		1 (2%)		
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)			

INTEGUMENTARY SYSTEM

Skin	(50)	(50)	(50)	(50)
Hemangioma				1 (2%)
Hemangiosarcoma			1 (2%)	
Squamous Cell Papilloma	1 (2%)			
Pinna, Neural Crest Tumor		1 (2%)		1 (2%)
Site Of Application, Subcutaneous Tissue, Hemangiosarcoma	1 (2%)	1 (2%)		
Subcutaneous Tissue, Fibrous Histiocytoma			1 (2%)	
Subcutaneous Tissue, Hemangiosarcoma	1 (2%)		2 (4%)	
Subcutaneous Tissue, Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)			

MUSCULOSKELETAL SYSTEM

Bone	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Harderian Gland				1 (2%)
Skeletal Muscle	(3)	(2)	(6)	(1)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (33%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Trimethylolpropane triacrylate

Time Report Requested: 09:26:54

Route: SKIN APPLICATION

CAS Number: 15625-89-5

First Dose M/F: 12/13/04 / 12/13/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
------------------	---------	-----------	-----------	-----------

Carcinoma, Metastatic, Pancreas	1 (33%)			
Hemangiosarcoma		1 (50%)	1 (17%)	
Hepatoblastoma, Metastatic, Liver			1 (17%)	
Hepatocholangiocarcinoma, Metastatic, Liver	1 (33%)			
Sarcoma			1 (17%)	
Schwannoma Malignant, Metastatic, Spinal Cord			1 (17%)	

NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(50)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)	
Meningioma Benign		1 (2%)		
Oligodendroglioma Malignant	1 (2%)			
Peripheral Nerve	(2)	(1)	(4)	(1)
Spinal Cord	(2)	(1)	(4)	(0)
Schwannoma Malignant			1 (25%)	

RESPIRATORY SYSTEM

Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	1 (2%)	5 (10%)	9 (18%)	4 (8%)
Alveolar/Bronchiolar Adenoma, Multiple		1 (2%)	1 (2%)	
Alveolar/Bronchiolar Carcinoma	10 (20%)	9 (18%)	3 (6%)	8 (16%)
Alveolar/Bronchiolar Carcinoma, Multiple	2 (4%)	2 (4%)		2 (4%)
Carcinoma, Metastatic, Harderian Gland				2 (4%)
Carcinoma, Metastatic, Pancreas	1 (2%)			
Hemangiosarcoma		1 (2%)		
Hepatoblastoma, Metastatic, Liver		1 (2%)	1 (2%)	1 (2%)
Hepatocellular Carcinoma, Metastatic, Liver	8 (16%)	2 (4%)	7 (14%)	10 (20%)
Hepatocholangiocarcinoma, Metastatic, Liver	2 (4%)		2 (4%)	
Nose	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Harderian Gland				1 (2%)
Trachea	(50)	(50)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Trimethylolpropane triacrylate

Time Report Requested: 09:26:54

Route: SKIN APPLICATION

CAS Number: 15625-89-5

First Dose M/F: 12/13/04 / 12/13/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
------------------	---------	-----------	-----------	-----------

SPECIAL SENSES SYSTEM

Eye	(48)	(47)	(41)	(47)
Harderian Gland	(50)	(49)	(49)	(50)
Adenoma	8 (16%)	7 (14%)	4 (8%)	5 (10%)
Carcinoma	3 (6%)			2 (4%)
Bilateral, Adenoma		1 (2%)		

URINARY SYSTEM

Kidney	(48)	(46)	(42)	(49)
Alveolar/Bronchiolar Carcinoma, Metastatic, Lung	1 (2%)			
Carcinoma, Metastatic, Pancreas	1 (2%)			
Hemangiosarcoma				1 (2%)
Hepatocholangiocarcinoma, Metastatic, Liver	1 (2%)		1 (2%)	
Renal Tubule, Adenoma	2 (4%)			
Renal Tubule, Carcinoma, Metastatic, Lung	1 (2%)			
Urethra	(0)	(1)	(2)	(3)
Urinary Bladder	(47)	(48)	(42)	(49)

SYSTEMIC LESIONS

Multiple Organ	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma		3 (6%)		
Leukemia Granulocytic			1 (2%)	
Lymphoma Malignant	2 (4%)	3 (6%)	4 (8%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Trimethylolpropane triacrylate

Time Report Requested: 09:26:54

Route: SKIN APPLICATION

CAS Number: 15625-89-5

First Dose M/F: 12/13/04 / 12/13/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE MALE

0 MG/KG

0.3 MG/KG

1.0 MG/KG

3.0 MG/KG

Tumor Summary for Males

Total Animals with Primary Neoplasms (b)	46	48	47	44
Total Primary Neoplasms	118	115	108	104
Total Animals with Benign Neoplasms	37	41	36	37
Total Benign Neoplasms	57	71	55	50
Total Animals with Malignant Neoplasms	38	28	32	36
Total Malignant Neoplasms	61	43	53	53
Total Animals with Metastatic Neoplasms	12	3	12	13
Total Metastatic Neoplasms	35	4	21	18
Total Animals with Malignant Neoplasms Uncertain Primary Site				
Total Animals with Neoplasms Uncertain- Benign or Malignant		1		1
Total Uncertain Neoplasms		1		1

*** END OF MALE ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors

Test Type: CHRONIC

Trimethylolpropane triacrylate

Time Report Requested: 09:26:54

Route: SKIN APPLICATION

CAS Number: 15625-89-5

First Dose M/F: 12/13/04 / 12/13/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
--------------------	---------	-----------	-----------	-----------

Disposition Summary

Animals Initially In Study	65	65	65	65
Early Deaths				
Accidentally Killed		1		
Moribund Sacrifice	8	7	8	7
Natural Death	3	11	12	13
Survivors				
Natural Death			1	
Terminal Sacrifice	39	31	29	30
Animals Examined Microscopically	50	50	50	50

ALIMENTARY SYSTEM

Esophagus	(50)	(50)	(50)	(50)
Gallbladder	(46)	(41)	(39)	(40)
Intestine Large, Cecum	(47)	(42)	(40)	(42)
Intestine Large, Colon	(47)	(44)	(41)	(44)
Liposarcoma, Metastatic, Mesentery				1 (2%)
Intestine Large, Rectum	(48)	(44)	(40)	(43)
Intestine Small, Duodenum	(47)	(42)	(40)	(39)
Adenoma				1 (3%)
Carcinoma	1 (2%)	1 (2%)		1 (3%)
Intestine Small, Ileum	(48)	(42)	(40)	(40)
Intestine Small, Jejunum	(47)	(41)	(41)	(40)
Carcinoma		1 (2%)		1 (3%)
Liver	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Pancreas		1 (2%)		
Fibrosarcoma, Metastatic, Skin			1 (2%)	
Hemangiosarcoma			3 (6%)	2 (4%)
Hepatoblastoma		3 (6%)		3 (6%)
Hepatoblastoma, Multiple		1 (2%)		
Hepatocellular Adenoma	11 (22%)	5 (10%)	9 (18%)	10 (20%)
Hepatocellular Adenoma, Multiple	23 (46%)	29 (58%)	22 (44%)	26 (52%)
Hepatocellular Carcinoma	9 (18%)	10 (20%)	5 (10%)	17 (34%)
Hepatocellular Carcinoma, Multiple	3 (6%)	3 (6%)	5 (10%)	2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Trimethylolpropane triacrylate

Time Report Requested: 09:26:54

Route: SKIN APPLICATION

CAS Number: 15625-89-5

First Dose M/F: 12/13/04 / 12/13/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Hepatocholangiocarcinoma			1 (2%)	2 (4%)
Liposarcoma, Metastatic, Mesentery				1 (2%)
Osteosarcoma, Metastatic, Bone				1 (2%)
Sarcoma, Metastatic, Skeletal Muscle			1 (2%)	
Sarcoma, Metastatic, Skin			1 (2%)	1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)			
Sarcoma, Metastatic, Uterus	1 (2%)			
Mesentery	(24)	(25)	(25)	(14)
Carcinoma, Metastatic, Pancreas		1 (4%)		
Fibrous Histiocytoma, Metastatic, Skeletal Muscle			1 (4%)	
Hemangioma			1 (4%)	
Hemangiosarcoma			1 (4%)	
Hepatoblastoma, Metastatic, Liver		1 (4%)		
Hepatocholangiocarcinoma, Metastatic, Liver			1 (4%)	1 (7%)
Liposarcoma				1 (7%)
Osteosarcoma, Metastatic, Bone				1 (7%)
Sarcoma, Metastatic, Skeletal Muscle			1 (4%)	
Sarcoma, Metastatic, Skin			1 (4%)	
Sarcoma, Metastatic, Uncertain Primary Site	1 (4%)			
Sarcoma, Metastatic, Uterus	1 (4%)			
Pancreas	(49)	(50)	(46)	(49)
Carcinoma		1 (2%)		
Hepatoblastoma, Metastatic, Liver		1 (2%)		
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)	1 (2%)
Liposarcoma, Metastatic, Mesentery				1 (2%)
Sarcoma, Metastatic, Skeletal Muscle			1 (2%)	
Sarcoma, Metastatic, Skin			1 (2%)	
Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)			
Salivary Glands	(50)	(50)	(50)	(49)
Stomach, Forestomach	(50)	(50)	(47)	(50)
Carcinoma, Metastatic, Pancreas		1 (2%)		
Liposarcoma, Metastatic, Mesentery				1 (2%)
Sarcoma, Metastatic, Uterus	1 (2%)			
Squamous Cell Papilloma	2 (4%)			
Stomach, Glandular	(49)	(46)	(43)	(47)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Trimethylolpropane triacrylate

Time Report Requested: 09:26:54

Route: SKIN APPLICATION

CAS Number: 15625-89-5

First Dose M/F: 12/13/04 / 12/13/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Liposarcoma, Metastatic, Mesentery				1 (2%)
Sarcoma, Metastatic, Skeletal Muscle			1 (2%)	
Sarcoma, Metastatic, Skin			1 (2%)	

CARDIOVASCULAR SYSTEM

Heart	(50)	(50)	(50)	(50)
Hemangiosarcoma		1 (2%)		
Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)			

ENDOCRINE SYSTEM

Adrenal Cortex	(50)	(50)	(46)	(50)
Sarcoma, Metastatic, Skin			1 (2%)	
Sarcoma, Metastatic, Uncertain Primary Site	2 (4%)			
Subcapsular, Adenoma		1 (2%)		
Adrenal Medulla	(50)	(48)	(45)	(50)
Pheochromocytoma Benign		1 (2%)	1 (2%)	1 (2%)
Pheochromocytoma Malignant	2 (4%)			
Islets, Pancreatic	(49)	(50)	(46)	(49)
Adenoma	2 (4%)		1 (2%)	1 (2%)
Parathyroid Gland	(47)	(47)	(44)	(48)
Carcinoma			1 (2%)	
Pituitary Gland	(49)	(47)	(49)	(50)
Pars Distalis, Adenoma	7 (14%)	5 (11%)	8 (16%)	
Pars Distalis, Carcinoma		1 (2%)		
Pars Intermedia, Adenoma		1 (2%)	1 (2%)	
Thyroid Gland	(49)	(49)	(45)	(48)
Follicular Cell, Adenoma		1 (2%)		1 (2%)
Follicular Cell, Carcinoma			1 (2%)	

GENERAL BODY SYSTEM

Tissue NOS	(3)	(2)	(4)	(0)
------------	-----	-----	-----	-----

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Trimethylolpropane triacrylate

Time Report Requested: 09:26:54

Route: SKIN APPLICATION

CAS Number: 15625-89-5

First Dose M/F: 12/13/04 / 12/13/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Carcinoma, Metastatic, Pancreas		1 (50%)		
Fibrosarcoma	1 (33%)			
Hepatocolangiocarcinoma, Metastatic, Liver			1 (25%)	
Osteosarcoma, Metastatic, Bone			1 (25%)	
Sarcoma, Metastatic, Uterus	1 (33%)			

GENITAL SYSTEM

Clitoral Gland	(49)	(48)	(49)	(49)
Squamous Cell Carcinoma, Metastatic, Vagina		1 (2%)		
Ovary	(47)	(49)	(45)	(48)
Carcinoma, Metastatic, Pancreas		1 (2%)		
Cystadenocarcinoma	1 (2%)			
Cystadenoma	1 (2%)	1 (2%)	1 (2%)	
Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)			
Uterus	(50)	(50)	(50)	(50)
Polyp Stromal		1 (2%)	2 (4%)	5 (10%)
Sarcoma	1 (2%)			
Sarcoma Stromal				1 (2%)
Vagina	(0)	(1)	(1)	(1)
Polyp				1 (100%)
Squamous Cell Carcinoma		1 (100%)		

HEMATOPOIETIC SYSTEM

Bone Marrow	(50)	(50)	(49)	(50)
Hemangiosarcoma			1 (2%)	
Sarcoma, Metastatic, Skin		1 (2%)		
Lymph Node	(10)	(7)	(16)	(10)
Fibrosarcoma, Metastatic, Skin			1 (6%)	
Sarcoma, Metastatic, Skin			1 (6%)	
Iliac, Osteosarcoma, Metastatic, Bone			1 (6%)	
Iliac, Sarcoma, Metastatic, Uncertain Primary Site	1 (10%)			

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Trimethylolpropane triacrylate

Time Report Requested: 09:26:54

Route: SKIN APPLICATION

CAS Number: 15625-89-5

First Dose M/F: 12/13/04 / 12/13/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Mediastinal, Hepatocholangiocarcinoma, Metastatic, Liver				1 (10%)
Mediastinal, Sarcoma, Metastatic, Skeletal Muscle			1 (6%)	
Mediastinal, Sarcoma, Metastatic, Skin			1 (6%)	
Mediastinal, Sarcoma, Metastatic, Uterus	1 (10%)			
Pancreatic, Hepatoblastoma, Metastatic, Liver		1 (14%)		
Renal, Sarcoma, Metastatic, Uncertain Primary Site	1 (10%)			
Lymph Node, Mandibular	(50)	(48)	(48)	(48)
Lymph Node, Mesenteric	(45)	(46)	(42)	(49)
Hemangiosarcoma				1 (2%)
Spleen	(49)	(48)	(44)	(48)
Hemangioma			1 (2%)	
Hemangiosarcoma		1 (2%)	1 (2%)	
Liposarcoma, Metastatic, Mesentery				1 (2%)
Sarcoma, Metastatic, Skin			1 (2%)	
Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)			
Thymus	(47)	(49)	(44)	(44)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)	
Liposarcoma, Metastatic, Mesentery				1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)			
Thymoma Malignant	1 (2%)			

INTEGUMENTARY SYSTEM

Mammary Gland	(50)	(50)	(50)	(50)
Carcinoma			1 (2%)	
Skin	(50)	(50)	(50)	(50)
Carcinoma, Metastatic, Pancreas		1 (2%)		
Fibroma				1 (2%)
Sarcoma	1 (2%)			
Squamous Cell Papilloma	1 (2%)			
Control, Subcutaneous Tissue, Hemangioma				1 (2%)
Site Of Application, Mast Cell Tumor Benign			1 (2%)	1 (2%)
Subcutaneous Tissue, Fibrosarcoma	3 (6%)		1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Trimethylolpropane triacrylate

Time Report Requested: 09:26:54

Route: SKIN APPLICATION

CAS Number: 15625-89-5

First Dose M/F: 12/13/04 / 12/13/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Subcutaneous Tissue, Hemangiosarcoma	2 (4%)	1 (2%)		2 (4%)
Subcutaneous Tissue, Melanoma Benign	1 (2%)			
Subcutaneous Tissue, Neural Crest Tumor	1 (2%)			
Subcutaneous Tissue, Sarcoma		1 (2%)	1 (2%)	1 (2%)

MUSCULOSKELETAL SYSTEM

Bone	(50)	(50)	(50)	(50)
Hemangiosarcoma			1 (2%)	
Osteosarcoma			2 (4%)	2 (4%)
Sarcoma, Metastatic, Skin		1 (2%)		
Skeletal Muscle	(8)	(3)	(4)	(3)
Carcinoma, Metastatic, Pancreas		1 (33%)		
Fibrous Histiocytoma			1 (25%)	
Hepatoblastoma, Metastatic, Liver		1 (33%)		
Hepatocholangiocarcinoma, Metastatic, Liver			1 (25%)	1 (33%)
Liposarcoma, Metastatic, Mesentery				1 (33%)
Osteosarcoma, Metastatic, Bone			1 (25%)	1 (33%)
Sarcoma	2 (25%)		1 (25%)	
Sarcoma, Metastatic, Uncertain Primary Site	1 (13%)			
Sarcoma, Metastatic, Uterus	1 (13%)			

NERVOUS SYSTEM

Brain	(50)	(50)	(50)	(50)
Osteosarcoma, Metastatic, Bone			1 (2%)	
Peripheral Nerve	(3)	(2)	(0)	(1)
Spinal Cord	(3)	(2)	(0)	(1)

RESPIRATORY SYSTEM

Lung	(50)	(50)	(50)	(50)
Alveolar/Bronchiolar Adenoma	3 (6%)	2 (4%)	3 (6%)	2 (4%)
Alveolar/Bronchiolar Carcinoma	2 (4%)	5 (10%)	5 (10%)	1 (2%)

a - Number of animals examined microscopically at site and number of animals with lesion

Test Type: CHRONIC

Trimethylolpropane triacrylate

Time Report Requested: 09:26:54

Route: SKIN APPLICATION

CAS Number: 15625-89-5

First Dose M/F: 12/13/04 / 12/13/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Carcinoma, Metastatic, Pancreas		1 (2%)		
Carcinoma, Metastatic, Thyroid Gland			1 (2%)	
Fibrosarcoma, Metastatic, Skin			1 (2%)	
Hepatoblastoma, Metastatic, Liver		1 (2%)		
Hepatocellular Carcinoma, Metastatic, Liver	3 (6%)	3 (6%)	3 (6%)	5 (10%)
Hepatocholangiocarcinoma, Metastatic, Liver			1 (2%)	2 (4%)
Liposarcoma, Metastatic, Mesentery				1 (2%)
Osteosarcoma, Metastatic, Bone			1 (2%)	2 (4%)
Sarcoma, Metastatic, Uncertain Primary Site	2 (4%)			
Sarcoma, Metastatic, Uterus	1 (2%)			
Nose	(50)	(50)	(50)	(50)

SPECIAL SENSES SYSTEM

Eye	(48)	(45)	(43)	(45)
Harderian Gland	(50)	(50)	(48)	(49)
Adenoma	5 (10%)	10 (20%)	11 (23%)	3 (6%)
Carcinoma	2 (4%)		2 (4%)	1 (2%)

URINARY SYSTEM

Kidney	(49)	(46)	(43)	(47)
Fibrosarcoma, Metastatic, Skin			1 (2%)	
Fibrous Histiocytoma, Metastatic, Skeletal Muscle			1 (2%)	
Liposarcoma, Metastatic, Mesentery				1 (2%)
Sarcoma, Metastatic, Uncertain Primary Site	1 (2%)			
Urinary Bladder	(48)	(48)	(46)	(48)
Carcinoma, Metastatic, Pancreas		1 (2%)		

SYSTEMIC LESIONS

Multiple Organ	*(50)	*(50)	*(50)	*(50)
Histiocytic Sarcoma	2 (4%)	1 (2%)		2 (4%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Trimethylolpropane triacrylate

Time Report Requested: 09:26:54

Route: SKIN APPLICATION

CAS Number: 15625-89-5

First Dose M/F: 12/13/04 / 12/13/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
Lymphoma Malignant	20 (40%)	13 (26%)	17 (34%)	17 (34%)

a - Number of animals examined microscopically at site and number of animals with lesion

* Number of animals with any tissue examined microscopically

Test Type: CHRONIC

Trimethylolpropane triacrylate

Time Report Requested: 09:26:54

Route: SKIN APPLICATION

CAS Number: 15625-89-5

First Dose M/F: 12/13/04 / 12/13/04

Species/Strain: MICE/B6C3F1

Lab: SRI

B6C3F1 MICE FEMALE	0 MG/KG	0.3 MG/KG	1.0 MG/KG	3.0 MG/KG
--------------------	---------	-----------	-----------	-----------

Tumor Summary for Females

Total Animals with Primary Neoplasms (b)	47	45	47	49
Total Primary Neoplasms	110	102	113	111
Total Animals with Benign Neoplasms	41	39	37	40
Total Benign Neoplasms	56	57	62	54
Total Animals with Malignant Neoplasms	38	32	37	33
Total Malignant Neoplasms	53	45	51	57
Total Animals with Metastatic Neoplasms	6	7	11	10
Total Metastatic Neoplasms	25	20	34	27
Total Animals with Malignant Neoplasms Uncertain Primary Site	2			
Total Animals with Neoplasms Uncertain- Benign or Malignant	1			
Total Uncertain Neoplasms	1			

*** END OF REPORT ***

a - Number of animals examined microscopically at site and number of animals with lesion

b - Primary tumors: all tumors except metastatic tumors